Welcome to our dedicated page for Bicycle Therapeutics SEC filings (Ticker: BCYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bicycle Therapeutics plc (NASDAQ: BCYC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Bicycle Therapeutics is a clinical-stage pharmaceutical company developing Bicycle molecules, Bicycle Drug Conjugates (BDC) and Bicycle Radioconjugates (BRC), and its filings offer detailed insight into its operations, governance and financial condition.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand how the company describes its Bicycle technology platform, clinical pipeline, collaboration revenue, research and development expenses, and other key aspects of its biotechnology business. Current reports on Form 8-K, such as those furnished for quarterly financial results and Board of Directors changes, provide timely information on material events, including clinical updates, cost realignment actions, and governance developments.
Because BCYC is listed on The Nasdaq Stock Market LLC through American Depositary Shares, its SEC filings also detail the securities registered under Section 12(b) of the Exchange Act and related listing information. Users interested in director and executive matters can look to proxy materials and 8-K items addressing appointments, compensation policies and inducement equity awards granted under the company’s 2024 Inducement Plan.
On Stock Titan, each BCYC filing is accompanied by AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify disclosures related to clinical trial progress, collaboration agreements, and financial runway commentary. The platform also surfaces insider-related filings such as Form 4 when available, enabling users to monitor reportable transactions by directors and officers alongside the company’s broader SEC reporting history.
BICYCLE THERAPEUTICS PLC ownership update: Westfield Capital Management Company, L.P. reports 0 shares of Common Stock, representing 0% of the class as of 02/28/2026. The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, dated 03/04/2026.
Bicycle Therapeutics plc reports significant institutional holdings in a Schedule 13G filing. As of February 25, 2026, Invus Public Equities, L.P. directly held 2,719,707 American Depositary Shares (ADSs) and Avicenna Life Sci Master Fund LP directly held 429,342 ADSs, each ADS representing one Ordinary Share, nominal value GBP 0.01 per share.
The filing states 49,929,952 Shares outstanding as of October 27, 2025. Related entities and principals—including Invus advisors and Mr. Raymond Debbane—are reported as having beneficial ownership interests; Mr. Debbane is shown with aggregate control of 3,149,049 ADSs (combined holdings noted above).
Bicycle Therapeutics plc received an amended Schedule 13G/A filing from Westfield Capital Management Company, L.P. reporting 0 shares beneficially owned of common stock, representing 0% as of 12/31/2025. The amendment is signed by Brandi McMahon, Vice President, Deputy Chief Compliance Officer, dated 03/03/2026.
Bicycle Therapeutics plc filed Amendment No. 2 to a Schedule 13G reporting that Westfield Capital Management Company, L.P. beneficially owned 0 shares of Common Stock as of 12/31/2025. The amendment is signed by Brandi McMahon and dated 03/03/2026.
Bicycle Therapeutics plc reports a Schedule 13G filing disclosing beneficial ownership of 3,236,000 American Depositary Shares, representing 4.99% of the class as reported.
The filing identifies Armistice Capital, LLC as investment manager to Armistice Capital Master Fund Ltd., with voting and dispositive power shared for the 3,236,000 ADS. Steven Boyd, as managing member of Armistice Capital, is also reported as a beneficial owner. The statement cites the holdings as of 12/31/2025 and is signed on 02/18/2026.
Westfield Capital Management Company, L.P. has reported beneficial ownership of 3,016,026 shares of Bicycle Therapeutics plc common stock, representing 6.04% of the class as of 12/31/2025.
Westfield has sole power to vote 2,801,276 shares and sole power to dispose of 3,016,026 shares, with no shared voting or dispositive power. The shares are owned of record by Westfield’s investment advisory clients, who are entitled to dividends and sale proceeds. Westfield states the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Bicycle Therapeutics reported that its Chief Financial Officer, Travis Thompson, received a grant of employee stock options on February 3, 2026. The award covers 58,000 options to buy ordinary shares at an exercise price of $6.49 per share.
The options were granted at no cost and are held directly. They vest over time: one-fourth of the total underlying shares vests on February 3, 2027, with the remaining options vesting in 36 equal monthly installments afterward, creating a multi-year retention and incentive structure.
Bicycle Therapeutics plc has appointed Travis Thompson as Chief Financial Officer, effective January 29, 2026, succeeding Alethia Young. Thompson previously served as Senior Vice President and Chief Accounting Officer and joined the company in 2018 before its IPO.
Under his new employment agreement, Thompson will receive a $500,000 base salary, a target annual cash bonus equal to 50% of salary, and an option to purchase 58,000 ordinary shares subject to standard vesting. He is eligible for severance of nine months’ salary and COBRA if terminated without cause or for good reason, increasing to 18 months’ salary, 18 months’ COBRA, a full target bonus and full equity vesting if this occurs within 12 months after a change in control.
Young will remain in an interim capacity through April 29, 2026 and then serve as a paid consultant. Her separation terms include nine months of base salary severance, a full 2025 bonus at target, a pro-rated 2026 bonus for the transition period, up to nine months of COBRA, and consulting fees of $2,000 per service day (up to five days per month), with continued vesting of outstanding equity awards during the consulting period.
Bicycle Therapeutics plc filed a current report to share that it issued a press release on January 12, 2026 describing its recent accomplishments and strategic priorities for 2026. The company furnished this press release as Exhibit 99.1 to the report.
The filing confirms that Bicycle Therapeutics’ American Depositary Shares trade on The Nasdaq Stock Market under the symbol BCYC, and it includes standard exhibit and signature information, with the report signed by the company’s Chief Financial Officer, Alethia Young.
Bicycle Therapeutics chief technology officer Michael Skynner reported new equity awards and related tax-share sales. On January 2, 2026, he received 50,000 restricted share units, each representing one ordinary share at $0, with one-fourth vesting on January 2, 2027 and the rest vesting in 12 equal quarterly installments. He also received an employee stock option for 100,000 ordinary shares at an exercise price of $7.08, vesting one-fourth on January 2, 2027 and the remainder in 36 equal monthly installments.
To cover statutory tax withholding obligations from RSU vesting and settlement, 3,045 ordinary shares were sold on January 2, 2026 at a weighted average price of $6.8 and 3,266 shares were sold on January 5, 2026 at a weighted average price of $6.46, as mandated by his award agreement. After these transactions, he directly owned 161,966 ordinary shares and 100,000 options.